Researchers from The University of Osaka find that only a small fraction of T cells may drive the robust anti-cancer response seen in breakthrough multiple myeloma immunotherapy.

Percentage of γδ T cells increased in multiple myeloma patients. (A) gating for γδ T cells in multiple myeloma patients; (B) gating for γδ T cells in healthy controls. - Increased CD8⁺ T cells (P < ...

According to the American Cancer Society, colorectal cancer is the second leading cause of cancer death. Enrichment of regulatory T cells (T-regs) in solid cancers is generally associated with poor ...

Persistent viral infections pose a unique challenge to the immune system. Prolonged antigen exposure drives T cells into a state of exhaustion — a ...

Cullinan Therapeutics’ T-cell engager, CLN-049, has been proven tolerable and safe in an early-stage study in relapsed or refractory acute myeloid leukaemia (r/r AML) and myelodysplastic syndrome (MDS ...

Immunotherapy has transformed cancer treatment, but persistent challenges, such as T cell exhaustion, limited persistence, and variability in response, continue to impact therapeutic success.

Ben-Gurion University of the Negev's Prof. Alon Monsonego had discovered that T helper lymphocytes, a subset of immune cells which regulate immunity, undergo functional changes with age. These changes ...

Over the last decade, the cellular cancer immunotherapy known as CAR T-cell therapy has roared to the rescue of many blood cancer patients. The engineered immune cells revolutionized treatment of ...